Literature DB >> 9259980

Increased inducible nitric oxide synthase in skeletal muscle biopsies from patients with chronic heart failure.

V Adams1, J Yu, S Möbius-Winkler, A Linke, C Weigl, L Hilbrich, G Schuler, R Hambrecht.   

Abstract

In addition to left ventricular pump failure and low cardiac output, structural and metabolic alterations of skeletal muscle are thought to contribute to exercise intolerance seen in patients with CHF. Studies using cardiac myocytes have implicated nitric oxide elaborated by inducible nitric oxide synthase (iNOS) as a potential agent associated with the genesis of dilated cardiomyopathy. The present study was designed to locate iNOS in the working skeletal muscle of patients with congestive heart failure. Specific antibodies were used to detect iNOS by immunohistochemistry in skeletal muscle biopsies (m. vastus lateralis) of 37 patients with left ventricular pump failure and 8 normal controls. The expression was restricted to skeletal muscle myocytes and was increased five- to ninefold in patients with chronic heart failure. There was no statistically significant difference in iNOS expression between patients with dilated cardiomyopathy and those with ischemic cardiomyopathy. The finding of a locally increased expression of iNOS and the experimental evidence that NO attenuates the contractile performance of the skeletal muscle suggest that the expression of iNOS may be responsible for the exercise intolerance seen in patients with chronic heart failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259980     DOI: 10.1006/bmme.1997.2598

Source DB:  PubMed          Journal:  Biochem Mol Med        ISSN: 1077-3150


  16 in total

Review 1.  Redox control of skeletal muscle atrophy.

Authors:  Scott K Powers; Aaron B Morton; Bumsoo Ahn; Ashley J Smuder
Journal:  Free Radic Biol Med       Date:  2016-02-18       Impact factor: 7.376

Review 2.  Dietary Nitrate and Skeletal Muscle Contractile Function in Heart Failure.

Authors:  Andrew R Coggan; Linda R Peterson
Journal:  Curr Heart Fail Rep       Date:  2016-08

Review 3.  Inducible nitric oxide synthase in human diseases.

Authors:  K D Kröncke; K Fehsel; V Kolb-Bachofen
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

4.  Effects of L-arginine on lower limb vasodilator reserve and exercise capacity in patients with chronic heart failure.

Authors:  Y Kanaya; M Nakamura; N Kobayashi; K Hiramori
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

5.  Progressive chronic heart failure slows the recovery of microvascular O2 pressures after contractions in the rat spinotrapezius muscle.

Authors:  Steven W Copp; Daniel M Hirai; Leonardo F Ferreira; David C Poole; Timothy I Musch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-09-03       Impact factor: 4.733

Review 6.  Unraveling new mechanisms of exercise intolerance in chronic heart failure: role of exercise training.

Authors:  Viviane M Conraads; Emeline M Van Craenenbroeck; Catherine De Maeyer; An M Van Berendoncks; Paul J Beckers; Christiaan J Vrints
Journal:  Heart Fail Rev       Date:  2013-01       Impact factor: 4.214

Review 7.  Mechanistic links between oxidative stress and disuse muscle atrophy.

Authors:  Scott K Powers; Ashley J Smuder; David S Criswell
Journal:  Antioxid Redox Signal       Date:  2011-06-17       Impact factor: 8.401

Review 8.  Physical training as an adjunct therapy in patients with congestive heart failure: patient selection, training protocols, results, and future directions.

Authors:  R Hambrecht; S Gielen; G Schuler
Journal:  Curr Cardiol Rep       Date:  1999-05       Impact factor: 2.931

Review 9.  Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training.

Authors:  Brian D Duscha; P Christian Schulze; Jennifer L Robbins; Daniel E Forman
Journal:  Heart Fail Rev       Date:  2008-02       Impact factor: 4.214

Review 10.  Effects of exercise training on inflammatory markers in patients with heart failure.

Authors:  Josef Niebauer
Journal:  Heart Fail Rev       Date:  2008-02       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.